Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
Status:
Terminated
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
AVE1625 is a new potent and selective cannabinoid 1 (CB1) antagonist in clinical development
for the treatment of cognitive impairment in patients diagnosed with schizophrenia.
The main objective of this study is to evaluate the efficacy on cognitive impairment of 3
doses of AVE1625 using a new cognitive battery called Measurement and Treatment Research to
Improve Cognition in Schizophrenia (MATRICS) in schizophrenic patients.
The secondary objectives are to measure the efficacy of AVE1625 on functional capacity of the
patients using a specific scale called University of California San Diego Performance-based
Skills Assessment 2 (UPSA2) and to assess the safety of the compound.